Tanzania Liver Diseases Therapeutics Market Report 2022 to 2030

Tanzania Liver Diseases Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Tanzania liver disease therapeutics market will reach a value of $15 Mn from $9 Mn in 2022, growing at a CAGR of 6.6% during 2022-2030. The liver disease therapeutics in Tanzania is dominated by a few domestic pharmaceutical companies such as Africa Pharmaceutical Company, Dexa Medica, and Elys Chemical Industries. The liver disease therapeutics market in Tanzania is segmented into different types of disease and different therapy types. Some of the major factors affecting the market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.

ID: IN10TZPH040 CATEGORY: Pharmaceuticals GEOGRAPHY: Tanzania AUTHOR: Dr. Vishwa Modhia

Buy Now

Tanzania Liver Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Tanzania liver disease therapeutics market will reach a value of $15 Mn from $9 Mn in 2022, growing at a CAGR of 6.6% during 2022-2030.

Tanzania is a low-income, developing country in East Africa bordering the Indian Ocean. In Tanzania, liver illness is a major public health concern, with viral hepatitis being the predominant cause. In Tanzania, the prevalence of chronic hepatitis B is believed to be over 10%, whereas the prevalence of chronic hepatitis C is considered to be around 2%. Both disorders can result in liver cirrhosis and cancer.

According to the latest WHO data published in 2020 liver disease deaths in Tanzania reached 6,586 or 2.23% of total deaths. The age-adjusted death rate is 26.48 per 100,000 population ranks Tanzania the 72^nd in the world. Tanzania's government spent 3.8% of its GDP on healthcare in 2020.

tanzania liver disease therapeutics market analysis

Market Dynamics

Market Growth Drivers

In Tanzania, like in other poor and middle-income countries, routine management of persons with HBV/HCV infection does not include treatment of HCV with antiviral medication followed by anti-HBV. Tanzanians rely heavily on traditional medicine, and several traditional herbal medicines have been linked to liver damage. This emphasizes the significance of regulating and monitoring traditional medicine use in the country. Tanzania is putting in place a regional cooperation strategy. Furthermore, the country receives international aid in the form of concessional loans.

Market Restraints

Hepatitis B is one of the world's most common infectious diseases, with a significant prevalence in most Sub-Saharan African countries. The complexity of its diagnosis and treatment presents a substantial management problem in resource-limited settings such as Tanzania, where most tests and medications are either unavailable or prohibitively expensive. Tanzania's pharmaceutical business is challenged by a lack of infrastructure, particularly insufficient storage facilities, which can have an impact on medicine quality and effectiveness.

Competitive Landscape

Key Players

Africa Pharmaceutical Company Ltd: Africa Pharmaceutical Company is a Tanzanian pharmaceutical company that produces a variety of therapeutic products, including those for liver disease. Its liver disease products include Silymarin and Ursodeoxycholic acid
Dexa Medica (T) Ltd: Dexa Medica is a Tanzanian pharmaceutical company that produces a range of therapeutics, including those for liver disease. Its liver disease products include Silymarin and Ursodeoxycholic acid
Elys Chemical Industries Ltd: Elys Chemical Industries is a Tanzanian pharmaceutical company that produces a variety of therapeutic products, including those for liver disease

Healthcare Policies and Reimbursement Scenarios

In Tanzania, the regulation of liver disease therapeutics is overseen by the Tanzania Food and Drugs Authority (TFDA), which is responsible for ensuring that all pharmaceutical products, including liver disease therapeutics, meet safety, efficacy, and quality standards. To be approved for use in Tanzania, liver disease therapeutics must be registered with the TFDA, and manufacturers must comply with Good Manufacturing Practices (GMP) and other regulatory requirements. In terms of reimbursement, the National Health Insurance Fund (NHIF) is responsible for providing health insurance coverage to Tanzanians.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Tanzania Liver Disease Therapeutics Segmentation

By Treatment Type (Revenue, USD Billion):

Chemotherapy
Antiviral Drugs
Vaccines
Immunosuppressants
Corticosteroids
Immunoglobulins
Targeted Therapy

By Disease Type (Revenue, USD Billion):

Non-alcoholic Fatty Liver Disease (NAFLD)
Autoimmune Diseases
Cancer
Hepatitis
Genetic Disorder
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.